Literature DB >> 25775393

Expression and significance of CDC25B, PED/PEA-15 in esophageal carcinoma.

Ming Wang1, Xiao-Yang Zhu, Liang Wang, Yu Lin.   

Abstract

OBJECTIVE: To explore the role of CDC25B, PED/PEA-15 in the development of esophageal carcinoma and its influence on the prognosis.
METHODS: Fluorescence quantitative real-time PCR and immunohistochemistry methods were used to analyze the expression of CDC25B, PED/PEA-15 in esophageal carcinoma. Moreover, survival analysis was done using the Kaplan-Meier method.
RESULTS: In 66 cases of esophageal cancer tissues, the relative content of CDC25B mRNA was 16.22 (13.93-18.90). The positive expression rate of CDC25B protein was 48.5%, significantly higher than normal mucosa tissues (0%) (p<0.01). The relative content of PED/PEA-15 mRNA was 12.47 (10.41-14.93). The positive expression rate of PED/PEA-15 protein was 68.2%, significantly higher than normal mucosa tissues (17.6%) (p<0.01). The CDC25B protein expression was correlated with differentiation grade and depth of invasion (p<0.05). The PED/PEA-15 protein expression was related to differentiation grade, lymph node metastasis, and depth of invasion (p<0.05). Survival analysis showed that the mean survival time of PED/PEA-15-positive expression group was lower compared with the negative expression group (χ(2)=5.549, p=0.018). Analysis of the relationship between CDC25B and PED/PEA-15 suggested that there was a positive correlation between them (r=4.061, p=0.044).
CONCLUSION: Both CDC25B and PED/PEA-15 play a certain role in the carcinogenesis of esophageal cancer, and PED/PEA-15 has a greater influence on postoperative survival time. They will be the new diagnostic/therapeutic targets in esophageal carcinoma.

Entities:  

Keywords:  CDC25B; PED/PEA-15; esophageal carcinoma; expression significance; survival analysis

Mesh:

Substances:

Year:  2015        PMID: 25775393     DOI: 10.1089/cbr.2014.1701

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  6 in total

1.  IGF2 mRNA binding protein 3 (IMP3) mediated regulation of transcriptome and translatome in glioma cells.

Authors:  Shruti Bhargava; Vikas Patil; Riyaz Ahmad Shah; Kumaravel Somasundaram
Journal:  Cancer Biol Ther       Date:  2017-12-19       Impact factor: 4.742

2.  METTL3 promotes cell cycle progression via m6A/YTHDF1-dependent regulation of CDC25B translation.

Authors:  Huifeng Li; Ying Zhong; Guangxu Cao; Hezhan Shi; Yiyao Liu; Lingfeng Li; Peidi Yin; Jialing Chen; Zhendong Xiao; Bin Du
Journal:  Int J Biol Sci       Date:  2022-05-01       Impact factor: 10.750

3.  Identification of Biomarkers Correlated with the TNM Staging and Overall Survival of Patients with Bladder Cancer.

Authors:  Sheng Li; Xiaoping Liu; Tongzu Liu; Xiangyu Meng; Xiaohong Yin; Cheng Fang; Di Huang; Yue Cao; Hong Weng; Xiantao Zeng; Xinghuan Wang
Journal:  Front Physiol       Date:  2017-11-28       Impact factor: 4.566

4.  Increased miR-424-5p expression in peripheral blood mononuclear cells from patients with pemphigus.

Authors:  Menglei Wang; Liuping Liang; Li Li; Kai Han; Qian Li; Yusheng Peng; Xuebiao Peng; Kang Zeng
Journal:  Mol Med Rep       Date:  2017-04-03       Impact factor: 2.952

5.  Cyclin-dependent kinase 5 promotes the growth of tongue squamous cell carcinoma through the microRNA 513c-5p/cell division cycle 25B pathway and is associated with a poor prognosis.

Authors:  Yixuan Li; Fan Yao; Zan Jiao; Xuan Su; Tong Wu; Jin Peng; Zhongyuan Yang; Weichao Chen; Ankui Yang
Journal:  Cancer       Date:  2022-02-10       Impact factor: 6.921

6.  Phosphoprotein enriched in diabetes (PED/PEA15) promotes migration in hepatocellular carcinoma and confers resistance to sorafenib.

Authors:  Cristina Quintavalle; Sravanth Kumar Hindupur; Luca Quagliata; Pierlorenzo Pallante; Cecilia Nigro; Gerolama Condorelli; Jesper Bøje Andersen; Katrin Elisabeth Tagscherer; Wilfried Roth; Francesco Beguinot; Markus Hermann Heim; Charlotte Kiu Yan Ng; Salvatore Piscuoglio; Matthias Sebastian Matter
Journal:  Cell Death Dis       Date:  2017-10-26       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.